R&D | May 21, 2026
QIAGEN and NVIDIA partner on AI drug discovery
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Subscribe To Our Newsletter & Stay Updated
